US Edition
Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics
- Aurora Cannabis Inc. has denied the incorrect claim about acquiring MedLeaf Therapeutics, stating it has had no such discussions or agreements.
- The company emphasized that there has been no statement or information filed regarding a transaction with MedLeaf Therapeutics.
- Earlier today, Aurora filed its financial statements for the fourth quarter and fiscal year ending March 31, 2025.
- Aurora serves both medical and consumer cannabis markets across multiple regions, emphasizing its focus on science and innovation.
47 Articles
47 Articles
Aurora Cannabis clears the air and denies MedLeaf acquisition news
Aurora Cannabis (TSX:ACB) issued a firm denial of recent misinformation circulating online regarding alleged acquisitions and strategic partnerships The company became aware of an article posted on a news website falsely claiming that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics A second article incorrectly reported that Aurora had signed a partnership with MediPharm (TSX:LABS) distribute medical cannabis in Germany and ot…
Aurora Denies $215M MedLeaf Acquisition Report
EDMONTON, Canada – Aurora Cannabis Inc. (NASDAQ: ACB) issued a formal denial Wednesday regarding widely circulated reports claiming the company planned to acquire New Zealand–based MedLeaf Therapeutics in a $215-million cash-and-stock transaction. The denial, published via PR Newswire, clarified that no such deal has been made or is under consideration. The initial report, published by Investing.com and echoed by a cannabis-industry trade journa…
Coverage Details
Bias Distribution
- 73% of the sources are Center
To view factuality data please Upgrade to Premium
